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Over the last decade, an increasing literature has been highlighting the benefits of introducing Multi-
criteria decision analysis (MCDA) in healthcare decision processes [1], including the emerging ISPOR good 
practices task force [2-3]. Based on decision theory dating back to the 1960s [4-7], MCDA constitutes a tool to 
address complex decisions involving multiple criteria, especially where other methods fail to consider more 
than outcome of interest. A set of criteria is first established; weights and scores are combined with 
performance data for each alternative. This allows to generate an estimate of the relative value of alternative 
courses of actions. The approach has advantages among which are exhaustiveness: MCDA can take into 
account the multiplicity of outcomes; flexibility: scores can be expressed in ordinal or numerical terms; 
inclusiveness: MCDA involves both experts and stakeholders in the evaluation process. It also has drawbacks, in 
particular controversy: some MCDA methods may lack theoretical foundations and the rigor of some 
applications of MCDA has been questioned [8]. However, these concerns can be addressed by adopting MCDA 
methods founded on expected utility theory and following established good practice [3]; subjectivity: the 
weighting framework is generally based on human judgment and, as such, can be subject to bias; nonetheless, 
the subjective judgment is inherent in the decisions being made and is not an artefact of MCDA; non-
comparability: the ad hoc aggregation of outcomes makes results context-dependent and difficult to transfer to 
other situations or cases. 
In France, the conceptual framework of MCDA was founded by Bernard Roy [4] and has since been 
applied to industrial and infrastructure investments [9-10]. Despite French academics’ role in the development 
of MCDA, there is a little use in HTA, except for a few attempts aiming at an assessment of medical devices in 
hospital-based HTA such as drug-eluting beads for trans-catheter arterial chemoembolization [11]. The 
objective of this editorial is to discuss the possible implementation of MCDA in the French HTA process. In 
addition, it could serve as a case-study highlighting the challenges of introducing MCDA in other countries’ HTA. 
As stated above, one downside of MCDA is that it covers a wide range of approaches, which differ 
mainly in the treatment of performance data and the elicitation of preferences. A recent classification 
suggested for use by HTA decision makers [12] distinguishes three categories, qualitative MCDA: the 
deliberating committee uses a performance matrix to derive a ranking of alternatives; quantitative MCDA: 
before deliberation, a value-measurement model based on explicit criteria weights is applied to the 
performance matrix; MCDA with decision rules:  the committee uses pre-defined decision rules to be applied to 
the performance matrix. This typology is used to examine the potential implementation of MCDA in the French 
HTA context. 
 
1. A qualitative MCDA is implicitly considered in reimbursement and price negotiation of drugs and medical 
devices 
The French National Authority for Health (HAS) does not formally include MCDA in its HTA. 
Reimbursement is based on clinical benefit as assessed by the Transparency Committee (CT) for drugs and the 
Medical Device and Health Technology Evaluation Committee for medical devices (CNEDIMTS), respectively. 
The Committee of Economic Evaluation and Public Health (CEESP) evaluates submissions (cost-effectiveness 
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and budget impact analyses) by manufacturers for innovative drugs and medical devices with a claimed added 
clinical benefit (major, important or moderate) and an expected sales revenue above €20 million over two 
years [13]. In the absence of willingness to pay threshold, CEESP provides the pricing committee of the ministry 
of health (CEPS) with opinions on the level of the incremental cost effectiveness ratios (ICERs), their 
uncertainty, and the budget impact in relation to the price claimed by the manufacturer. 
The assessment of clinical benefit by CT and CNEDIMTS can be considered as a form of qualitative 
MCDA with time-consistent and transparent criteria. For example, the clinical benefit of a drug comprises: (1) 
severity of the disease and its impact on morbidity and mortality; (2) clinical efficacy, effectiveness and safety; 
(3) type of the drug: preventive, symptomatic or curative; (4) position in treatment strategy compared to 
alternatives; (5) impact on public health (e.g., burden of disease). However, the deliberative process resulting 
in a recommendation for reimbursement does not use pre-defined criteria weights and does not involve any 
inputs beyond those from health professionals of the two committees. 
2. Using quantitative MCDA in price negotiations for drugs and medical devices is challenging 
There are several quantitative MCDA frameworks that could potentially support HTA. Nobody denies 
the benefits of quantitative MCDA in enhancing transparency and in integrating preference dimensions that are 
not usually captured by quality-adjusted life year (QALY) through a framework based on explicit and pre-
specified criteria. However, the current implementation of quantitative MCDA raises several issues. 
In price negotiations with manufacturers, economic evaluations (called efficiency opinions in the 
French HTA context) are being used by CEPS as one criterion among other predefined-criteria such as added 
clinical benefit, prices of comparators, expected sales volume, and the European reference price [14]. A 
quantitative MCDA could in principle fit in but is difficult to implement in practice as long as negotiations 
regarding discounts and rebates remain confidential. Moreover, policy-makers may not want to commit to a 
common set of weights for these criteria, seeing their decisions as context-dependent and reflecting the 
heterogeneous preferences of the public stakeholders involved.  
Beyond these institutional considerations, the implementation of quantitative MCDA in HTA [15-20] 
has met two major criticisms related to the way it has been used to date [1-2, 8, 21-23]: (1) the additive value 
model simply combines criteria and their weights. It cannot accommodate overlapping criteria and non-
independence of preferences. For example, the EVIDEM (Evidence and value: Impact on decision making) 
framework [16] provides a performance matrix that includes overlapping economic criteria such as budget 
impact, cost-effectiveness, and impact on other expenditures. Furthermore, these criteria cannot be perceived 
as benefit attributes [21]; (2) the connection between the scaling of criteria and weights is ambiguous [8]. This 
is particularly problematic for innovative interventions (e.g., tumor-agnostic treatments), where the range of 
treatment benefits (e.g. overall survival) and key safety parameters (e.g. adverse reaction) is often unknown. 
These criticisms can be overcome by implementing an elicitation process that reflects the 
multiplicative nature of preferences. However, other questions will emerge: do policy-makers really need to 
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know the preferences of stakeholders regarding trade-offs between benefits and costs of health technologies? 
And if the answer is yes, how can one estimate the opportunity cost that supports funding decision in such a 
framework? More specifically, how can one measure the ICER threshold? Today, to the best of our knowledge, 
there are no MCDA applications addressing these issues for reimbursement and pricing decisions. 
3. Combining MCDA with decision rules to improve the HTA deliberation process 
Without explicitly using MCDA terminology, HTA agencies may apply decision-making rules designed 
to better structure their deliberation process. Specifically, NICE uses a threshold of £20,000 per QALY gained 
but may adopt a higher threshold for special conditions and therapies (e.g., end-of-life treatments). 
In the case of France, the inclusion of decision rules permitting to adjust the cost-effectiveness and 
budget impact analyses is certainly a promising perspective. It may enhance the consistency of efficiency 
assessments providing improved guidance in price negotiations. However, it is challenging to define decision 
rules in the absence of a willingness-to-pay threshold. Even in the presence of such a threshold, the rules 
governing adjustments to specific contexts (e.g. innovation) or disease characteristics (e.g. orphan disease, 
end-of-life treatment) need to be specified. This may call for a pilot project aiming to re-structure the 
deliberation process concerning drugs and medical devices, in particular by clarifying the role of economic 
evaluation. 
 
4. Conclusion  
This contribution examined how MCDA could be included in the French HTA process. Despite its 
expected benefits, implementing quantitative MCDA seems premature at this point. Too many issues have to 
be resolved to be able to derive consistent estimates of the trade-offs between benefits and costs. However, 
MCDA with decision rules may constitute a promising compromise once a cost effectiveness threshold has 
been adopted. Yet, MCDA with decision rules would call for a transparent and consistent framework to avoid 
controversy and to make economic evaluation comparable across therapies. Such an investigation exploring its 
feasibility may be initiated by academic researchers and French healthcare authorities.  
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